A multicenter study to examine renal protection by a combination of an HMG-CoA reductase inhibitor and losartan in patients with dyslipidemia associated with IgA nephropathy
- Conditions
- IgA nephropathy
- Registration Number
- JPRN-UMIN000002887
- Lead Sponsor
- Fukuoka University Faculty of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 80
Not provided
1.Patients with type 1 diabetes mellitus 2.Patients with cardiovascular disease and with the following conditions Patients who have undergone coronary artery bypass grafting (CABG) or percutaneous transluminal coronary angioplasty (PTCA) within the last 3 months, patients with unstable angina, patients with a history of myocardial infarction, patients with a history of a transient ischemic attack (TIA) within the last 6 months, patients that are NYHA functional class III or IV or with heart failure, and patients with a history of cerebral infarction within the last 3 months 3. serum Cr>2.5mg/dL or eGFR<30mL/min 4.Patients with severe liver dysfunction 5.Patients with secondary hypertension caused by factors other than diabetes mellitus 6.HbA1c > 9% 7.Patients with pregnancy or nursing 8.Other patients deemed ineligible by an investigator
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method